Thus, while both PDX1 and MAFA have been demonstrated to play essential roles in α-to-β reprogramming, identifying efficient methods to generate surrogate β cells, which will lead to the establishment of regenerative therapies for people with diabetes, still remains a challenge. This evidence concerns the gene MAFA and diabetes mellitus.